Role of gemistocytes in astrocytoma progression

Laboratory Investigation

Volumn 76, Issue 2, 1997, Pages 277-284

  Watanabe, Kunihiko ^a   Tachibana, Osamu ^a   Yonekawa, Yasuhiro ^b   Kleihues, Paul ^a,b   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; ASTROCYTOMA; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADULT; ASTROCYTES; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NEOPLASM STAGING; POINT MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031056494     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Alderson LM, Castleberg RL, Harsh GR IV, Louis DN, and Henson JW (1995). Human gliomas with wild-type p53 express bcl-2. Cancer Res 55:999-1001.
2. Burger PC and Kleihues P (1989). Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer 63:2014-2023.
3. Burger PC and Scheithauer BW (1994). Tumors of the central nervous system. Washington, D.C.: Armed Forces Institute of Pathology.
4. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, and Gerdes J (1992). Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357-363.
5. de Jong D, Prins FA, Mason DY, Reed JC, van Ommen GB, and Kluin PM (1994). Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 54:256-260.
6. Elledge RM and Lee WH (1995). Life and death by p53. Bioessays 17:923-930.
7. Eng LF and Ghirnikar RS (1994). GFAP and astrogliosis. Brain Pathol 4:229-237.
8. Hockenbery DM (1995). bcl-2: A novel regulator of cell death. Bioessays 17:631-638.
9. Hockenbery DM, Zutter M, Hickey W, Nahm M, and Korsmeyer SJ (1991). BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965.
10. Hoshino T, Wilson BC, and Ellis WG (1975). Gemistocytic astrocytes in gliomas: An autoradiographic study. J Neuropathol Exp Neurol 34:263-281.
11. Kleihues P, Burger PC, and Scheithauer BW (1993a). Histological typing of tumours of the central nervous system: World Health Organization International histological classification of tumours, 2nd ed. Berlin: Springer-Verlag.
12. Kleihues P, Burger PC, and Scheithauer BW (1993b). The new WHO classification of brain tumours. Brain Pathol 3:255-268.
13. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, and Reed JC (1993). Investigation of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53:4701-4714.
14. Kros JM, Stefanko SZ, de Jong AA, van Vroonhoven CC, van der Heul RO, and van der Kwast TH (1991). Ultrastructural and immunohistochemical segregation of gemistocytic subsets. Hum Pathol 22:33-40.
15. Krouwer HG, Davis RL, Silver P, and Prados M (1991). Gemistocytic astrocytomas: A reappraisal. J Neurosurg 74: 399-406.
16. Lantos PL, Vandenberg SR, and Kleihues P (1996). Tumours of the nervous system. In: Graham DI and Lantos PL, editors. Greenfield's neuropathology, vol 2, 6th ed. London: Arnold, 583-879.
17. Laping NJ, Teter B, Nichols NR, Rozovsky I, and Finch CE (1994). Glial fibrillary acidic protein: Regulation by hormones, cytokines, and growth factors. Brain Pathol 4:259-275.
18. LeBrun DP, Warnke RA, and Cleary ML (1993). Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 142:743-753.
19. Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett S, and Herman B (1995). Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 57:509-521.
20. Nakasu S, Nakasu Y, Nioka H, Nakajima M, and Handa J (1994). bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 88:520-526.
21. Nissl F (1904). Zur Histopathologie der paralytischen Rindenerkrankung. Histol Histopathol Arb Grosshirn 1:315.
22. Onda K, Davis RL, Wilson CB, and Hoshino T (1994). Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme. Acta Neuropathol (Berl) 87:586-593.
23. Paulus W, Grothe C, Sensenbrenner M, Janet T, Baur I, Graf M, and Roggendorf W (1990). Localization of basic fibroblast growth factor, a mitogen and angiogenic factor, in human brain tumors. Acta Neuropathol (Berl) 79:418-423.
24. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, and Mason DY (1990). Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137:225-232.
25. Piris MA, Pezzella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, and Rilke F (1994). p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 69:337-341.
26. Reed JC (1994). Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6.
27. Russell DS and Rubinstein LJ (1989). Pathology of tumours of the nervous system, 5th ed. London: Edward Arnold.
28. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, and Clarke MF (1994). c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91:5878-5882.
29. Schiffer D, Chio A, Giordana MT, Leone M, and Soffietti R (1988). Prognostic value of histologic factors in adult cerebral astrocytoma. Cancer 61:1386-1393.
30. Schiffer D (1993). Brain tumors. Pathology and its biological correlates. Berlin: Springer-Verlag.
31. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, and Levin B (1995). bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55:237-241.
32. Stefanik DF, Rizkalla LR, Soi A, Goldblatt SA, and Rizkalla WM (1991). Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 51:5760-5765.
33. Tsujimoto Y, Cossman J, Jaffe E, and Croce CM (1985). Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443.
34. Wang Y, Szekely L, Okan I, Klein G, and Wiman KG (1993). Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8:3427-3431.
35. Watanabe K, Ogata N, von Ammon K, Yonekawa Y, Nagai M, Ohgaki H, and Kleihues P (1996). Immunohistochemical assessments of P53 protein accumulation and tumor growth fraction during the progression of astrocytomas. In: Nagai M, editor. Brain tumour research and therapy. Tokyo: Springer-Verlag, 255-262.
36. Watanabe K, Sato K, Bienat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, and Ohgaki H (in press, 1997). Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res
37. Weller M, Malipiero U, Aguzzi A, Reed JC, and Fontana A (1995). Protooncogene bcl-2 gene transfer abrogates Fas/ APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95:2633-2643.